The GSM-related study had two objectives: first, to determine what women know about GSM. Data related to menopausal treatments have already been partially published elsewhere. This study is part of a population survey known as the COMEM (“COnocimiento de las Mujeres Españolas en Menopausia” in Spanish) study. To make an informed choice, it is important that women have good knowledge about GSM that is free of myths and false beliefs. The term 'empowered therapy' has even been introduced in some publications. There is an increasing tendency among clinicians to share the treatment options for vulvovaginal atrophy with the patient.

If women are aware of the genital changes produced by hormonal decline and how this can affect their sexuality, it would be easier to identify women with dysfunction or possible symptoms that require treatment. Although sexuality is an important element of the lives of many midlife women, only a very small percentage of midlife women report having discussed their sexual problems with a healthcare professional. Genitourinary syndrome of menopause (GSM) is one of the most frequent complaints referred in transition and postmenopause and it could impact on the quality of life and sexual function of women. Adherence to treatments during the coronavirus confinement has been worryingly low. Most women do not talk to their gynecologist about sexuality. There is great lack of knowledge of the treatments used for GSM. Reduced sexual activity ( p > 0.001) and coronavirus diagnosis ( p = 0.003) were significantly associated with poorer treatment compliance. During the coronavirus confinement period, adherence to treatments for vulvovaginal atrophy was poor in 72.5% asked (n = 204). Comparative analyses were conducted according to age, menopausal status, type of menopause, place of residence, type of health care received and level of education.

Lubricants were the best-known treatments (69.6%), followed by local estrogens (25.7%) 66% of the women did not speak to their gynecologist about sexuality. Vaginal dryness was the most frequently identified symptom (74.3%). ResultsĪ sample of 2355 women were included. An extension study of treatment adherence was conducted during the coronavirus pandemic between March and April 2020. Multi-center observational study including women between 35 and 75 years. To study knowledge regarding genitourinary syndrome of menopause (GSM) and the treatments for it and to analyze treatment adherence during the COVID-19 confinement.

Spss 12 free download windows 7